Needham analyst Gil Blum initiated coverage of Solid Biosciences (SLDB) with a Buy rating and $16 price target
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SLDB:
- Solid Biosciences receives Rare Pediatric Disease designation of SGT-212
- Solid Biosciences management to meet with Citizens JMP
- Citizens JMP healthcare analysts hold an analyst/industry conference
- Strategic Advancements and Growth Potential: Solid Biosciences’ Buy Rating Validated by Key Partnerships and Regulatory Progress
- Solid Biosciences announces licensing agreement with Andelyn Biosciences